• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

FDA Drug Shortages

  • Print
  • Share
  • E-mail

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Search Results

 Cidofovir Injection

 Status: Discontinuation

 » Therapeutic Categories: Antiviral; Pediatric

Gilead Sciences, Inc. (Revised 07/31/2014)

Company Contact Information:
Gilead Medical Information (1-800-445-3235) [Option 2], Monday to Friday 8:00 a.m. to 5:00 p.m. Pacific Time.

Presentation Posting Date Related Information
VISTIDE (cidofovir injection) 75 mg/mL for intravenous infusion, is supplied as a non-preserved solution in single-use clear glass vials as follows: 375 mg in a 5 mL vial in a single-unit carton (NDC 61958-0101-1) 07/31/2014 Discontinuation of the manufacture of the drug. Due to a decreasing incidence of CMV retinitis in adults with AIDS, Gilead Sciences, Inc. (Gilead) has discontinued the marketing of Vistide (cidofovir injection) 75 mg/mL. Physicians can continue to use alternative medicinal products which are available to treat patients with CMV retinitis or access cidofovir injection through generic manufacturers.